# US 2015/0104414 A1 · Cytokines and neuroantigens for treatment of immune disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104414 A1
- Document ID: US20150104414A1
- Status: Published application
- Kind: A1
- Application number: 14/518,705
- Filed: 2014-10-20
- Published: 2015-04-16
- Earliest claimed: 2009-03-31
- Assignees: East Carolina University
- Applicants: East Carolina University
- Inventors: Mark D. Mannie
- Web page: https://patentgrep.com/patent/US20150104414A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 38/1709: {from mammals}
- A61K 38/21: Interferons {[IFN]}
- A61K 38/215: {IFN-beta}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 9/12: Antihypertensives
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- C07K 14/565: IFN-beta
- C12N 9/6424: {Serine endopeptidases (3.4.21)}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/577: {tolerising response}
- A61K 2039/6031: {Proteins}
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides methods of regulating an immunological disorder comprising administering to a subject an effective amount of (i) an autoimmune antigen in conjunction with (ii) an anti-inflammatory cytokine. Compositions including the same are also provided.

## Claims

### Claim at position 1

1-35. (canceled)

### Claim 36

A composition comprising:
(a) at least one fusion protein comprising (i) an autoimmune antigen selected from the group consisting of myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG) and myelin-associated oligodendrocytic basic protein, or portions thereof; (ii) optionally an enterokinase linking moiety, wherein the enterokinase linking moiety is (1) an amino acid sequence of SEQ ID NO:1, (2) an amino acid sequence having at least 80% identity or homology with the amino acid sequence of SEQ ID NO:1, (3) an amino acid sequence encoded by a nucleic acid sequence encoding an enterokinase recognition site, or (4) an amino acid sequence encoded by a nucleic acid sequence that hybridizes with the complement of the nucleic acid sequence of (3) under stringent conditions as represented by hybridization conditions of 0.5M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C. and wash conditions of 0.1×SSC/0.1% SDS at 68° C.; and (iii) an anti-inflammatory cytokine;
(b) an anti-inflammatory cytokine; and
(c) a pharmaceutically acceptable carrier, excipient or diluent.

### Claim 37 (depends on 36)

The composition of claim 36, wherein at least one of the anti-inflammatory cytokines is macrophage colony-stimulating factor (M-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), or IFN-β.

### Claim 38 (depends on 36)

The composition of claim 36, wherein the autoimmune antigen or portion thereof is selected from the group consisting of myelin basic protein (MBP), proteolipid protein (PLP), and myelin oligodendrocyte glycoprotein (MOG), or portions thereof.

### Claim 39 (depends on 36)

The composition of claim 36, wherein the anti-inflammatory cytokine of the fusion protein is IFN-β or GM-CSF.

### Claim 40 (depends on 36)

A method of treating multiple sclerosis comprising administering to a subject an effective amount of the composition of claim 36.

### Claim 41 (depends on 40)

The method of claim 40, wherein the composition is administered parenterally.

### Claim 42 (depends on 36)

A method of modulating a cellular immune response comprising administering the composition of claim 36 to a subject or a cell culture comprising T cells or thymocytes in an amount sufficient to elicit a tolerogenic response.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cellular immune response is antigen-specific.

### Claim 44 (depends on 42)

The method of claim 42, wherein said administering step is carried out in vivo.

### Claim 45 (depends on 42)

The method of claim 42, wherein said administering step is carried out ex vivo in a cell culture comprising T cells or thymocytes.

### Claim 46 (depends on 42)

The method of claim 42, wherein the tolerogenic response is an active tolerance mechanism.

### Claim 47 (depends on 42)

The method of claim 42, wherein the tolerogenic response is a sustained tolerogenic response.

### Claim 48 (depends on 36)

A kit comprising one or more containers having pharmaceutical dosage units comprising an effective amount of the composition of claim 36, wherein the container is packaged with optional instructions for the use thereof.

### Claim 49 (depends on 36)

A method of modulating antigen-presenting cell function comprising exposing an antigen-presenting cell in a subject or a cell culture comprising thymocytes to the composition of claim 36.

### Claim 50 (depends on 36)

The composition of claim 36, wherein:
the autoimmune antigen or portion thereof of the at least one fusion protein is myelin oligodendrocyte glycoprotein (MOG) and the anti-inflammatory cytokine of the fusion protein is granulocyte-macrophage colony stimulating factor (GM-CSF); and
the anti-inflammatory cytokine of (b) is IFN-β.

### Claim 51 (depends on 36)

The composition of claim 36, wherein:
the autoimmune antigen or portion thereof of the at least one fusion protein is myelin oligodendrocyte glycoprotein (MOG) and the anti-inflammatory cytokine of the fusion protein is IFN-β; and
the anti-inflammatory cytokine of (b) is IFN-β.

### Claim 52 (depends on 40)

The method of claim 40, wherein the subject is a human subject.

### Claim 53 (depends on 36)

A method of preventing multiple sclerosis comprising administering to a subject an effective amount of the composition of claim 36.

### Claim 54 (depends on 40)

The method of claim 40, wherein the autoimmune antigen or portion thereof of the at least one fusion protein is proteolipid protein (PLP) and the anti-inflammatory cytokine is IFN-β; and
the anti-inflammatory cytokine of (b) is IFN-β.
